Low-Cost Single-Port (LoCoSP) Device for a Transcervical Approach in Minimally Invasive Transhiatal Esophagectomy
September 11th, 2021
2.5K views
Here, we describe a step-by-step description of transhiatal esophagectomy and the development of a low-cost single-port device for a transcervical approach in a minimally invasive transhiatal esophagectomy.
Overview
This article presents a step-by-step protocol for performing minimally invasive transhiatal esophagectomy using a novel, low-cost single-port device to facilitate upper mediastinal dissection via a transcervical approach. The technique aims to improve lymph node harvesting and reduce operative morbidity in patients with advanced esophageal cancer.
Key Study Components
Area of Science
- Surgical oncology
- Minimally invasive surgery
- Esophageal cancer treatment
Background
- Esophagectomy is the standard curative treatment for advanced esophageal cancer.
- The optimal surgical approach (transthoracic vs. transhiatal) remains debated due to differences in morbidity and lymph node dissection efficacy.
- Minimally invasive transhiatal esophagectomy can reduce operative trauma and complications but is limited in upper mediastinal access.
- A low-cost single-port device was developed to enhance transcervical mediastinal dissection and lymphadenectomy.
Purpose of Study
- To describe the construction and application of a low-cost single-port device for transcervical mediastinoscopic dissection during minimally invasive transhiatal esophagectomy.
- To demonstrate the feasibility and safety of this approach for upper mediastinal and esophageal dissection.
- To improve lymph node harvesting, particularly along the left recurrent laryngeal nerve and paratracheal regions.
Methods Used
- Construction of a single-port device using a nasogastric tube, sterile glove, sponge, and three 5-mm trocars.
- Laparoscopic access to the peritoneal cavity for initial inspection and lymphadenectomy.
- Transhiatal dissection of the lower mediastinum and esophagus.
- Transcervical mediastinoscopic approach using the single-port device for upper mediastinal dissection and lymphadenectomy.
- Mobilization and removal of the esophagus, creation of a gastric tube, and cervical anastomosis.
Main Results
- The single-port device enabled safe and effective dissection of the upper mediastinum, including the esophagus over the aortic arch and behind the trachea.
- Improved lymph node harvesting along the left recurrent laryngeal nerve and paratracheal areas was achieved.
- Direct visualization reduced the risk of tracheal injury and hemorrhage from major vessels.
- From 2018 to 2020, 12 patients underwent this procedure with successful outcomes.
Conclusions
- The low-cost single-port device is a practical and effective tool for transcervical mediastinoscopic dissection during minimally invasive transhiatal esophagectomy.
- This approach enhances lymphadenectomy and surgical safety in the upper mediastinum.
- It offers a cost-effective solution for improving outcomes in esophageal cancer surgery.
Frequently Asked Questions
What is the main advantage of the low-cost single-port device in esophagectomy?
It enables safe and effective transcervical dissection of the upper mediastinum, improving lymph node harvesting and reducing the risk of injury to critical structures.
What materials are used to construct the single-port device?
The device is made from a nasogastric tube, a sterile number-eight glove, a sterile sponge, and three permanent 5-mm trocars.
How does this technique improve lymphadenectomy?
It allows for direct visualization and dissection of lymph nodes along the left recurrent laryngeal nerve and paratracheal regions, which are difficult to access with standard transhiatal approaches.
What are the key steps in the surgical procedure?
Key steps include laparoscopic abdominal access, lymphadenectomy, transhiatal and transcervical esophageal dissection, and cervical anastomosis using a gastric tube.
How many patients have undergone this procedure as described?
Twelve patients with esophageal carcinoma underwent this procedure between 2018 and 2020.
Does the use of this device compromise cancer recurrence or survival?
No, the minimally invasive approach with the single-port device does not compromise cancer recurrence or survival, while reducing operative trauma and morbidity.
What are the potential complications addressed by this technique?
The technique minimizes respiratory complications, tracheal injury, and hemorrhage from major vessels during upper mediastinal dissection.
Executive Industry Relevance
Advancing minimally invasive surgical techniques for esophageal cancer addresses a critical need for reducing operative morbidity while maintaining oncologic rigor. The low-cost single-port transcervical device enhances upper mediastinal access, supporting more comprehensive lymphadenectomy and safer dissection in anatomically challenging regions. This innovation strengthens procedural reproducibility and may inform future device development for complex oncologic resections.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables precise anatomical dissection, supporting validation of surgical targets in upper mediastinal oncology.
- Improves functional assessment of lymph node harvesting techniques relevant to disease progression studies.
- Facilitates mechanistic de-risking by reducing procedural variability in preclinical surgical models.
Screening & Assay Development
- Standardizes the surgical environment for evaluating device performance and procedural endpoints.
- Supports reproducible collection of tissue samples for downstream molecular or histopathological assays.
- Enables quantitative assessment of lymph node yield and dissection completeness.
Translational & Preclinical Research
- Aligns surgical technique with disease-relevant anatomical models for translational oncology research.
- Improves continuity between preclinical device evaluation and clinical implementation in esophageal cancer surgery.
- Supports risk-adjusted advancement of surgical innovations targeting upper mediastinal disease.
Pipeline & Workflow Integration
This device-driven approach integrates into the surgical innovation pipeline from preclinical validation through translational research and clinical feasibility studies.
- Discovery Biology: Enhances hypothesis testing for surgical access and lymphadenectomy strategies in upper mediastinal oncology.
- Screening: Provides a reproducible platform for evaluating device safety, efficacy, and tissue yield metrics.
- Analytics: Enables quantitative comparison of lymph node retrieval and procedural safety endpoints.
- Translational Research: Bridges preclinical device testing with clinical workflow adaptation in minimally invasive esophagectomy.
- Enterprise Reuse: Offers a scalable, cost-effective solution adaptable to diverse surgical and anatomical research settings.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in surgical outcomes and target accessibility.
- Operational Value: Promotes standardization, reproducibility, and cost efficiency in complex surgical procedures.
- Strategic Value: Supports informed go/no-go decisions for device development and procedural adoption.
- Portfolio Impact: Enables risk-adjusted prioritization of surgical innovations targeting high-morbidity oncologic indications.
Implementation Considerations
- Requires surgical expertise in minimally invasive and transcervical approaches.
- Needs access to basic laparoscopic instrumentation and custom device assembly materials.
- Demands cross-team standardization for procedural reproducibility and safety monitoring.
- Adaptation may be necessary for anatomical variations or different oncologic models.
- Potential limitations include technical learning curve and anatomical access constraints.
Biopharma FAQs
Why does null hypothesis testing matter for transcervical lymphadenectomy?
Null hypothesis testing ensures that observed improvements in lymph node yield and safety with the single-port device are statistically significant, supporting robust target validation in surgical oncology workflows.
How does independent variable isolation apply to upper mediastinal dissection?
Isolating the device as the independent variable allows teams to attribute changes in dissection quality and safety directly to the single-port innovation, clarifying its mechanistic impact within the surgical pipeline.
What do quantitative lymph node measurements enable in device evaluation?
Quantitative assessment of lymph node retrieval provides objective endpoints for comparing device performance, informing go/no-go decisions and supporting reproducibility across studies.
Why are replication requirements critical for cross-functional surgical teams?
Replication ensures that the device's safety and efficacy can be consistently achieved across operators and settings, facilitating cross-team adoption and enterprise-level standardization.
What statistical analysis capabilities are needed before device implementation?
Robust statistical analysis is required to validate improvements in safety and lymphadenectomy, ensuring that device adoption is based on reproducible, data-driven evidence rather than anecdotal outcomes.
Chapters in this video
0:00
Introduction
0:37
Fabrication of the Low-Cost Single-port (LoCoSP) Device
2:56
Transhiatal Esophagectomy- Abdominal Cavity Inventory
3:19
Open Gastrocolic Ligament
3:39
Dissection of the Celiac Trunk
4:18
Ligation of the Left Gastric Vessels
4:47
Dissection of the Esophageal Hiatus
5:24
Dissection of the Esophagus in the Lower Mediastinum
6:29
Dissection of the Structures of the Upper Mediastinum using LoCoSP Device
7:29
Making the Gastric Tube and Esophagogastric Anastomosis
